Existing investor Novo has taken part in a $28m round for Nerre Therapeutics, a GlaxoSmithKline spinout focusing on neuronal hypersensitivity treatments.

Nerre Therapeutics, a UK-based developer of treatments for neuronal hypersensitivity, has raised £23m ($28m) in series B funding from investors including pharmaceutical firm Novo.

The round was co-led by venture capital firm Fountain Healthcare Partners, VC fund Forbion Capital Partners and investment firm OrbiMed, with participation from VC firm Advent Life Sciences.

Pharmaceutical company GlaxoSmithKline (GSK) spun Nerre out in 2012 to develop its portfolio of NK receptor antagonists in order to combat conditions caused by neuronal hypersensitivity. NK receptors…